Back to search results

HPARSS for Sensory Deficit Screening in Childhood Cancer Survivors

This study aims to improve how quickly and effectively sensory problems are found in children who have survived cancer. Researchers at Washington University School of Medicine are using a tool called HPARSS (Highlighting Patients at Risk for Sensory Screening). This tool identifies survivors at risk for sensory deficits (problems with sight, hearing, etc.) based on their past cancer treatments. The goal is to help doctors screen, diagnose, and treat these issues sooner. You may be able to join if you are between 7 and 17 years old, were diagnosed with pediatric cancer, completed treatment at least 6 months but less than 2 years ago, and are followed at the Washington University School of Medicine's Pediatric Hematology/Oncology Program. The study will measure how many at-risk patients are identified, how many fail screening tests, and how many receive further testing or treatment.

Study design
This is an interventional study with a planned enrollment of 146 participants. It uses a cross-sectional design to identify at-risk patients and prompt screening.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for up to 1 year and 9 months after screening tests are completed.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05582551

Patients At Risk for Sensory Screening (HPARSS) to Enhance Sensory Deficit Screening in Childhood Cancer Survivors

Recruiting
NAAges 7–17InterventionalHealth services
Washington University School of Medicine
~146 participants
Updated 2026-06-15 on ClinicalTrials.gov
What's tested:Highlighting Patients at Risk for Sensory Screening (HPARSS)

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percentage of patients with at risk for sensory deficits identified by HPARSS
Measured over Through completion of enrollment for all patients (estimated to be 9 months)
+2 more outcomes measured

Conditions

Childhood Cancer

Explore related trials

Childhood Malignant Neoplasm

Where it's being run

1 sites across 1 states
Missouri1

Study leadership

  • Robert J Hayashi, M.D. · PRINCIPAL_INVESTIGATOR · Washington University School of Medicine

Who to contact

Robert J Hayashi, M.D.
[email protected]
314-454-6018
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients with a diagnosis of pediatric cancer (diagnosis at \<18 years of age)
Treatment including chemotherapy and/or radiation therapy
Completion of all cancer therapy for at least 6 months and less than 2 years
Followed in the Division of Pediatric Hematology/Oncology Program at the Washington University School of Medicine
Current age between 7 and 17 years of age (age where all of the screening tests are both valid and have been successfully performed by our group)
English speaking

Exclusion

Undergoing active cancer treatment
Patient under the care of the Late Effects Program at St. Louis Children's Hospital
Received previous diagnostic testing or rehabilitative therapy for a secondary deficit eligible for screening.
Parents and/or patient illiteracy
No contact with treatment team in the past two years
In foster care or without a legal guardian

What this trial measures

  • Percentage of patients with at risk for sensory deficits identified by HPARSSThrough completion of enrollment for all patients (estimated to be 9 months)
  • Percentage of at risk patients who fail the assigned screening testThrough completion of enrollment for all patients (estimated to be 9 months)
  • Percentage of patients in need of referral for screen test results who participate in formal diagnostic testing and/or treatmentThrough 1 year after the completion of screening test for all participants (estimated to be 1 year and 9 months)